

UC San Diego

UC San Diego Previously Published Works

Title

Structural insights into binding specificity, efficacy and bias of a β_2 AR partial agonist.

Permalink

<https://escholarship.org/uc/item/18x9z7xq>

Journal

Nature chemical biology, 14(11)

ISSN

1552-4450

Authors

Masureel, Matthieu
Zou, Yaozhong
Picard, Louis-Philippe
et al.

Publication Date

2018-11-01

DOI

10.1038/s41589-018-0145-x

Peer reviewed



Published in final edited form as:

Nat Chem Biol. 2018 November ; 14(11): 1059–1066. doi:10.1038/s41589-018-0145-x.

Structural insights into binding specificity, efficacy and bias of a β_2 AR partial agonist

Matthieu Masureel^{#1}, Yaozhong Zou^{#1,12}, Louis-Philippe Picard², Emma van der Westhuizen^{2,12}, Jacob P. Mahoney^{3,12}, João P.G.L.M. Rodrigues^{1,4,5}, Thomas J. Mildorf^{6,12}, Ron O. Dror^{6,12}, David E. Shaw^{6,7}, Michel Bouvier², Els Pardon^{8,9}, Jan Steyaert^{8,9}, Roger K. Sunahara¹⁰, William I. Weis^{1,5}, Cheng Zhang^{11,*}, and Brian K. Kobilka^{1,*}

¹Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, California, USA.

²Department of Biochemistry, Institute for Research in Immunology and Cancer, Université de Montreal, Montreal, Québec, Canada.

³Department of Pharmacology, University of Michigan, Ann Arbor, Michigan, USA.

⁴Department of Computer Science, Stanford University, Stanford, California, USA.

⁵Department of Structural Biology, Stanford University, Stanford, California, USA.

⁶D. E. Shaw Research, New York, NY 10036, USA.

⁷Department of Biochemistry and Molecular Biophysics, Columbia University, New York, New York, USA.

⁸Structural Biology Brussels, Vrije Universiteit Brussel, Brussels, Belgium.

⁹Structural Biology Research Center, VIB, Brussels, Belgium.

Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms

*To whom correspondence should be addressed: chengzh@pitt.edu, kobilka@stanford.edu.

¹²Present addresses: Y.Z.: Geneus Technologies, Ltd, Chengdu, Sichuan, People's Republic of China. E.W.: Monash Institute for Pharmaceutical Sciences, Monash University, Victoria, Australia; J.P.M.: Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, California, USA. T.M.: Dropbox, New York, New York, USA; R.O.D.: Department of Computer Science and Institute for Computational and Mathematical Engineering, Stanford University, Stanford, California, USA.

Author Contributions

C.Z. and Y.Z. expressed and purified the receptor and nanobody for crystallography studies, collected X-ray diffraction data and solved the crystal structure. M.M. developed the Atto655 reporter system, purified and labeled receptors used in fluorescence studies, collected spectroscopic data, and performed radioactive ligand binding assays. L.P.P. generated mutants of N293 and S204. E.W. and L.P.P. performed Gs activation and β -arrestin2 recruitment BRET assays under supervision from M.B. J.M. performed octet red experiments under supervision from R.S. J.P.G.L.M.R. performed modeling and sampling of the Atto655 dye on the receptor structures. T.J.M. and R.O.D. performed and analyzed MD simulation studies. R.O.D. and D.E.S. oversaw MD simulations and analysis. E.P. generated the nanobody library and performed the initial selections. J.S. supervised nanobody production. W.I.W. supervised and assisted with the structure refinement. M.M., C.Z. and B.K.K. interpreted data, made figures and wrote the manuscript. B.K.K. provided overall project supervision.

Competing Interests Statement

The BRET-based biosensors used in the present study are licensed to Domain Therapeutics but are freely available from M.B. for non-commercial academic use. M.B. is the chair of the Scientific Advisory Board of Domain Therapeutics. B.K.K. is a co-founder of and consultant for ConfometRx.

Data Availability

Atomic coordinates and the structure factors for the crystal structure have been deposited with the Protein Data Bank under accession code 6CSY. Other data and results are available upon request.

¹⁰Department of Pharmacology, University of California San Diego School of Medicine, La Jolla, California, USA.

¹¹Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.

These authors contributed equally to this work.

Abstract

Salmeterol is a partial agonist for the β_2 adrenergic receptor (β_2 AR), and the first long-acting β_2 AR agonist (LABA) to be widely used clinically for the treatment of asthma and chronic obstructive pulmonary disease. Salmeterol has been controversial both for its safety and mechanism of action. To understand its unusual pharmacological action and partial agonism, we obtained the crystal structure of salmeterol-bound β_2 AR in complex with an active-state stabilizing nanobody. The structure reveals the location of the salmeterol exosite, where sequence differences between β_1 AR and β_2 AR explain the high receptor subtype selectivity. A structural comparison with the β_2 AR bound to the full agonist epinephrine reveals differences in the hydrogen bond network involving residues Ser 204^{5,43} and Asn 293^{6,55}. Mutagenesis and biophysical studies suggest that these interactions lead to a distinct active-state conformation that is responsible for the partial efficacy of G protein activation and the limited β -arrestin recruitment for salmeterol.

Introduction

G-protein coupled receptors (GPCRs) are able to respond to a large variety of ligands with different efficacy profiles for specific signaling pathways¹: full agonists that maximally stimulate; partial agonists that produce submaximal stimulation even at fully saturating concentrations; inverse agonists that suppress the basal signaling; and neutral antagonists that bind to the receptor without stimulating or inhibiting basal signaling. Among these categories, partial agonists are often better tolerated as therapeutics compared with full agonists².

Salmeterol is a partial agonist for the human β_2 -adrenergic receptor (β_2 AR). As a potent bronchodilator, it is among the most prescribed drugs for the treatment of asthma and chronic obstructive pulmonary disease (COPD)³. Compared to some other β_2 AR agonists such as isoproterenol and salbutamol, salmeterol exhibits two desirable pharmacological properties. First, salmeterol is able to distinguish β_2 AR from β_1 AR for selective stimulation (1400- to 3000-fold selectivity)⁴, thereby minimizing cardiac toxicity⁵. Second, salmeterol belongs to the class of long-acting β_2 AR agonists (LABAs) with a duration of action up to 12 hours, in contrast to the short-acting β_2 AR agonists such as salbutamol with only a 4–6 hour duration of action^{6–8}. Those pharmacological properties of salmeterol have contributed to its successful use in treating asthma and COPD for more than two decades. However, LABAs used alone, especially salmeterol, have been implicated, in several clinic trials, to be associated with increased mortality in asthmatics. This liability is mitigated when LABAs are combined with an inhaled corticosteroid^{9–11}.

The high selectivity and long-acting properties of salmeterol have been attributed to its unusual bitopic structure. In addition to the saligenin ethanolamine pharmacophore that replaces the catecholamine structure of the endogenous β_2 AR ligand epinephrine (also known as adrenaline), salmeterol contains an extra moiety of an aryloxyalkyl tail consisting of a phenol ring with an eleven-atom ether chain (Fig. 1a). While the pharmacophore binds to the orthosteric site responsible for receptor activation, the aryloxyalkyl tail is proposed to bind to an additional site (exosite), providing additional interactions responsible for the high receptor-subtype selectivity and the slow dissociation rate contributing to its long duration of action¹². Previous mutagenesis and biochemical studies to locate the exosite have led to conflicting results^{4,12–16}. Salmeterol is also of interest in being a functionally selective β_2 AR partial agonist with a 5- to 20-fold bias towards Gs over arrestin^{17,18}. Previous studies revealed that, compared to isoproterenol, activation of the β_2 AR by salmeterol leads to slower initial rates of G protein-coupled receptor kinase (GRK) phosphorylation with similar maximal degrees of phosphorylation^{19,20}, but strongly reduced arrestin-mediated receptor internalization and desensitization^{17,21,22}, contributing to the prolonged therapeutic effect of salmeterol in bronchial dilation as a result of β_2 AR stimulation. This signaling bias may contribute to the advantageous therapeutic profile of salmeterol by maintaining bronchodilation through Gs-mediated signaling while minimizing arrestin-mediated β_2 AR desensitization, and avoiding arrestin-dependent pro-inflammatory effects^{23,24}.

Recent progresses in the structural characterization of β adrenergic receptors, especially the crystal structures of active β_2 AR bound to full agonists BI-167107 or epinephrine (also known as adrenaline), with either a Gs protein or active-state stabilizing nanobody, as well as the crystal structures of inactive avian β_1 AR bound to a variety of full and partial agonists, have greatly advanced our understanding of the pharmacology and activation of β adrenergic receptors^{25–29}. In an effort to further understand the molecular basis for the unusual pharmacological properties of salmeterol and its partial agonism, we obtained the crystal structure of salmeterol-bound human β_2 AR in an active state stabilized by a conformation-specific nanobody, Nb71. The structure reveals the location of the exosite and provides a structural explanation for the high receptor-subtype selectivity and distinct signaling behavior of salmeterol.

Results

Nanobody Nb71 stabilizes the salmeterol-bound β_2 AR

It has been shown for the β_2 AR and the μ -opioid receptor (μ OR) that agonists alone are not sufficient to stabilize the receptors in active conformational states^{27,30–32}. As a result, the active-state structures of the β_2 AR and μ OR have required either a G protein or conformation-specific camelid antibody fragments (nanobodies) to stabilize the active states of the receptors^{25,26,29}. The first active-state structure of a hormone-activated GPCR was obtained using a nanobody named Nb80, which was obtained from a llama immunized with β_2 AR bound to the ultra high-affinity full agonist BI-167107 reconstituted into phospholipid vesicles²⁵. The structures of β_2 AR in the β_2 AR-Nb80 complex and the β_2 AR-Gs complex are very similar^{25,26}. However, evidence from biophysical studies suggest that partial

agonists may stabilize distinct states³³, so Nb80 may not be the best candidate to stabilize salmeterol-bound β_2 AR.

While Nb80 preferentially binds to agonist-occupied β_2 AR over antagonist-occupied β_2 AR²⁵, Octet Red studies show that Nb80 also preferentially binds to β_2 AR bound to BI-167107 and epinephrine over β_2 AR bound to salmeterol (Supplementary Table 1). Moreover, Nb80 has a greater effect on enhancing the binding affinity of the agonist isoproterenol than on the partial agonist salmeterol (Supplementary Fig. 1). We therefore selected another nanobody, Nb71, generated from the same immunization that produced Nb80. Nb71 preferentially binds to agonist-occupied β_2 AR³⁴, but in contrast to Nb80, has no preference for these catecholamines over salmeterol (Supplementary Table 1, Supplementary Fig. 1). Therefore, we chose Nb71 to stabilize the salmeterol-bound β_2 AR for structural characterization.

Structural features of Nb71-stabilized β_2 AR

We used an engineered β_2 AR with T4 lysozyme (T4L) fused to its N-terminal region and a truncated intracellular loop3 (referred to as T4L- β_2 AR- ICL3 hereafter) to crystallize β_2 AR bound to salmeterol. Previous studies have demonstrated that T4L- β_2 AR- ICL3 exhibits similar ligand binding and G protein activating properties as the wild type β_2 AR³⁷. Using this construct, we obtained crystals of the β_2 AR-salmeterol-Nb71 complex by the lipidic cubic phase (LCP) method³⁵. A complete data set was obtained by merging data from 23 crystals and the structure was determined to a resolution of 3.0 Å (**Fig. 1b,c**; Supplementary Table 2). Like Nb80, Nb71 binds to the cytoplasmic surface of the receptor with its third complementarity-determining region (CDR3) loop inserted into a hydrophobic cavity formed by residues from transmembrane helices (TMs) 3, 5, 6 and 7 (**Fig. 1b**, Supplementary Fig. 2), yet Nb71 stabilizes a conformation that is distinct from that stabilized by Nb80 (Supplementary Fig. 2).

The active-state conformation of the receptor in the β_2 AR-salmeterol-Nb71 complex resembles that of the BI-167107-bound β_2 AR in complex with Nb80 (PDB ID 3P0G, rmsd = 1.0 Å) or with Gs (PDB ID 3SN6, rmsd = 1.3 Å) more than the inactive-state conformation of the receptor in the inverse agonist carazolol-bound β_2 AR structure (PDB ID 2RH1, rmsd = 1.9 Å)^{25,26}. Indeed, the structural features associated with receptor activation²⁵, including the outward movement of TM6 at the cytoplasmic side associated with the conformational changes of the core triad residues Pro 211^{5,50}, Ile 121^{3,40} and Phe 282^{6,44}, as well as the slightly contracted ligand-binding pocket at the extracellular side, are all observed in the structure of β_2 AR-salmeterol-Nb71 complex when compared to the inactive β_2 AR (Fig. 2a-c). However, the Nb71-stabilized β_2 AR shows some distinct structural features compared to the Nb80- and Gs-stabilized β_2 AR. Relative to the inactive β_2 AR, the Nb71-stabilized β_2 AR displays a smaller outward movement of the cytoplasmic end of TM6 (8Å) than the Nb80-stabilized β_2 AR (11Å) or Gs-stabilized β_2 AR (13Å) (Fig. 2a). There is also a slightly smaller counter-clockwise rotation of TM6 in the Nb71-stabilized β_2 AR when viewed from the cytoplasmic surface, as shown by the position of Glu268 (Fig. 2b). While this current structure clearly shows an active-state conformation of β_2 AR, the smaller conformational rearrangements observed for TM6 upon activation compared to the changes seen for the

active-state stabilized β_2 AR bound to Nb80 or Gs suggest a less active or a partially active conformational state of β_2 AR stabilized by Nb71. It is tempting to speculate that such partially active conformational state may closely resemble a salmeterol-stabilized conformation of β_2 AR that is less efficient at coupling to Gs. However, the conformation of TM6 is primarily stabilized by interactions with Nb71 and may not reflect the conformation stabilized by salmeterol alone.

Exosite binding of salmeterol

The location and the molecular details of the exosite for the aryloxyalkyl tail of salmeterol are of great interest because of its association with the high receptor selectivity, high affinity and long-lasting action properties of salmeterol. The clear electron density map of salmeterol based on our structure allowed us to unambiguously define the structural basis of the exosite (**Figs. 3a,b & Supplementary Figs. 3,4**). The crystal structure shows that the aryloxyalkyl tail of salmeterol extends towards the extracellular surface of the receptor, occupying a cleft formed by residues from extracellular loop2 (ECL2), ECL3 and the extracellular ends of TM6 and TM7. Interactions between salmeterol and the exosite are mediated primarily through extensive van der Waals and hydrophobic interactions (Fig. 3c). The phenol ring of the tail also forms π - π interactions with the surrounding aromatic residues Phe 194^{ECL2}, Tyr 308^{7,35} and His 296^{6,58} (Ballesteros-Weinstein numbers), in agreement with previous studies reporting a 5- to 18-fold decrease of salmeterol affinity caused by mutating those residues⁴. In addition, the ether oxygen atom of the tail forms a hydrogen bond with the main chain amide group of residues Phe 193^{ECL2} (Fig. 3a). It acts as a 'hinge' point where the tail of salmeterol bends almost 90° to fit the exosite. Previous studies indicated that shifting the ether oxygen in the aryloxyalkyl tail or removing it substantially reduces the affinity of salmeterol for β_2 AR²¹, suggesting an important role of this hydrogen bond in the exosite binding (Supplementary Fig. 5). All those additional interactions in the exosite contribute to the 1000-fold higher affinity of salmeterol compared to salbutamol, a short-acting β_2 AR agonist (SABA) which shares the same orthosteric pharmacophore as salmeterol but lacks the long aryloxyalkyl tail³⁶ (Fig. 1a).

The exosite binding also explains the very high selectivity of salmeterol for β_2 AR over β_1 AR (>3000-fold)³⁶. β_1 AR and β_2 AR share a very high overall structural similarity (rmsd of carazolol-bound avian β_1 AR and human β_2 AR = 0.58 Å, PDB IDs 2YCW & 2RH1, respectively) and sequence similarity (92% in TM segments for human β_1 AR and β_2 AR, Supplementary Fig. 6). In particular, all residues that form the orthosteric binding pocket, with the exception of Y308 are identical in β_1 AR and β_2 AR. In contrast, the exosite is relatively divergent in those two receptors. Salmeterol achieves high receptor selectivity by sampling this divergent region with its long aryloxyalkyl tail (**Fig. 3d**, Supplementary Fig. 6). Such selectivity determinants do not apply to salbutamol, which only has about 20-fold selectivity for β_2 AR over β_1 AR³⁶. Our results are in agreement with extensive chimeric receptor and site-directed mutagenesis studies recently reported by Baker et al.⁷, who observed the K305D and H296K mutations in the β_2 AR to have a substantial effect on salmeterol affinity while having little effect on salbutamol affinity.

The salmeterol exosite in β_2 AR is reminiscent of the well-defined allosteric site in the M2 muscarinic receptor (M2R)³⁷. The M2R represents one of the most extensively characterized model systems for allosteric regulation. Fig. 3e shows a comparison of the exosite in the β_2 AR and the binding site for the positive allosteric modulator LY2119620 revealed by the active-state crystal structure of M2R bound to the orthosteric agonist iperovo and LY2119620³⁷. The similarity between those two sites suggests the potential for allosterically regulating β_2 AR activity by small molecules that target the exosite. On the other hand, the bitopic nature of salmeterol with two-site binding on β_2 AR supports the feasibility of developing highly selective bitopic compounds for other GPCRs including muscarinic receptors³⁸.

Polar interactions within the orthosteric binding site

While the interactions between the aryloxyalkyl tail of salmeterol and the exosite in the extracellular vestibule of β_2 AR confer the high affinity and selectivity of salmeterol, they are not responsible for its efficacy and signaling bias. Salmeterol and salbutamol exhibit similar signaling properties including partial agonism and the selective activation of Gs over arrestin and Gi (Supplementary Fig. 7)¹⁷, despite their differences in affinity and receptor selectivity. Considering that salmeterol and salbutamol only share the saligenin ethanolamine pharmacophore (Fig. 1a), the interactions between this shared pharmacophore and the receptor within the orthosteric binding pocket are likely to be responsible for their shared signaling properties. In the orthosteric binding site, the alkylamine and β -hydroxyl groups of salmeterol form hydrogen-bonding interactions with Asp 113^{3,32} and Asn 312^{7,39} and the saligenin group forms hydrogen-bonding interactions with Ser 203^{5,42} and Ser207^{5,46}, similar to those observed for β_2 AR bound to the full agonist epinephrine (**Figs. 4a,b**). In the structure of β_2 AR bound to epinephrine, the hydrogen bonding interactions with Ser 203^{5,42} and Ser207^{5,46} are associated with the inward movement of TM5 around those two serine residues, which is further linked to the rearrangement of the core triad residues and the outward movement of the cytoplasmic end of TM6²⁹. For salmeterol, the two saligenin hydroxyl groups also form direct hydrogen bonding interactions with Ser 203^{5,42} and Ser 207^{5,46}. However, compared to epinephrine, these interactions with salmeterol may have a weaker effect on stabilizing the inward movement of TM5 because of the additional methylene between the meta position hydroxyl group and the phenyl ring.

In epinephrine-bound β_2 AR, Asn 293^{6,55} forms a hydrogen bond with Ser 204^{5,43} and the meta-hydroxyl of epinephrine. This polar network is not observed in salmeterol-bound β_2 AR. Asn 293^{6,55} and Ser 204^{5,43} have previously been shown to be important for the binding of epinephrine but not for the binding of antagonists^{39,40}. To further investigate the possible role of these polar networks in ligand efficacy, we used molecular dynamics simulations to characterize the stability of specific ligand-receptor hydrogen bonds that would be expected to stabilize the inward movement of TM5 and the rotation of TM6 observed in active state structures of the β_2 AR (Fig. 5a). These simulations show that salmeterol forms less stable hydrogen bonds with Asn293^{6,55} and Asn312^{7,39} than does epinephrine. Salmeterol forms a more stable hydrogen bond with Ser203^{5,42}, but apparently only because its longer hydroxymethyl group can maintain this hydrogen bond better than epinephrine's hydroxyl group even when TM5 moves away from its crystallographic

position. Thus, while the salmeterol-bound crystal structure captured a binding pocket conformation similar to that observed for full agonist, molecular dynamics simulations suggest that this active conformation is stabilized less by salmeterol than by epinephrine, with the most dramatic difference observed for Asn293^{6,55}. To further characterize the role of Asn 293^{6,55} and Ser 204^{5,43} interactions, we examined the effects of mutating these residues on β -arrestin2 recruitment and Gs activation by bioluminescence resonance energy transfer (BRET) between membrane anchored GFP and luciferase-tagged arrestin or luciferase-tagged Gs and GFP-tagged $G_{\beta 1}/G_{\gamma 1}$, respectively^{41,42} (**Fig. 5b,c & Supplementary Table 3**). For all the mutations we tested in the presence of isoproterenol, a catecholamine similar to epinephrine, we observe a dramatic reduction in β -arrestin2 recruitment (**Fig. 5b, left panel**), and a more moderate reduction in Gs activation (**Fig. 5c, left panel**). This suggests an important role of these two residues in regulating bias, either by directly modulating arrestin coupling, or by altering GRK phosphorylation and hence arrestin binding. Interestingly, the same mutations, with the exception of S204T, had a less pronounced effect on the ability of salmeterol to activate Gs (**Fig. 5c, right panel**), and all mutants showed very little or no salmeterol-induced arrestin recruitment, similar to wild-type β_2 AR (**Fig. 5b, right panel**). Thus, the absence of the hydrogen bonds between Asn 293^{6,55} and salmeterol may account for the weak β -arrestin recruitment, as well as the lower efficacy in Gs activation of salmeterol-bound β_2 AR compared to β_2 AR bound to full agonist.

Spectroscopic insights into salmeterol-bound β_2 AR

The differences in efficacy and signaling bias between salmeterol and the full agonist epinephrine suggest that salmeterol may stabilize a distinct conformation. Previous single molecule Förster resonance energy transfer (FRET) studies suggested a smaller outward displacement of TM6 in β_2 AR bound to salmeterol compared to β_2 AR bound to epinephrine or BI167107⁴³. In addition, cellular assays using a BRET-based β_2 AR conformational sensor⁴⁴ confirmed the reduced propensity of salmeterol to promote the outward movement of TM6 (**Supplementary Fig. 8**). Nevertheless, these RET studies cannot distinguish the following two mechanistic possibilities: 1- salmeterol stabilizes the same conformation of TM6 as epinephrine, but for a smaller receptor population; 2- salmeterol stabilizes a distinct TM6 conformation. To further investigate the differences at the cytoplasmic end of TM6 upon activation between salmeterol-bound and epinephrine-bound β_2 AR in the absence of conformation-stabilizing nanobodies, we performed steady-state spectroscopic studies on purified, labeled receptor in detergent with two different reporter systems (**Supplementary Fig. 9a**). We used β_2 AR labeled at Cys 265 with the fluorophore monobromobimane (mBBBr or bimane), which we previously used as a conformational reporter of β_2 AR activation^{31,45}, and developed a new fluorescent reporter system using an engineered β_2 AR labeled at residue 266 with the fluorophore Atto655.

The bimane fluorophore has been extensively used to report on activation of β_2 AR^{25,45,46} as well as other GPCRs^{47,48}, as it is very sensitive to its chemical environment. In the inactive state, bimane attached at the cytoplasmic end of TM6 is in a hydrophobic environment. Upon receptor activation, the intracellular end of TM6 undergoes an outward and “unwinding” motion (**Fig. 6a**) that shifts bimane to a more polar and solvent-exposed

environment, resulting in a decrease in fluorescence intensity and a red-shift in λ_{max} . Agonists alone produce a 10–20% decrease in intensity and ~ 10 nm red-shift in λ_{max} . Further changes are observed upon G protein coupling. Using this reporter system, we find that even though salmeterol has a higher binding affinity to $\beta_2\text{AR}$ than epinephrine⁶, epinephrine causes a larger reduction in intensity and red-shift in λ_{max} of bimane compared to salmeterol when both ligands are used at saturating concentrations (Fig. 6b). This suggests that salmeterol stabilizes $\beta_2\text{AR}$ in conformations with on average a smaller outward movement or rotation of TM6. In addition, we observe that Gs induces a similar bimane response with salmeterol as with epinephrine (Fig. 6b, “+Gs” curves), indicating that once coupled to Gs, the $\beta_2\text{AR}$ adopts a similar TM6 conformation no matter what agonist is bound at the extracellular region, consistent with previous single molecule FRET studies³³. Nevertheless, the extent to which salmeterol-bound receptor couples to Gs appears to be slightly lower, as the change in λ_{max} and fluorescence intensity is slightly less pronounced compared to epinephrine-bound receptor.

To complement the bimane-based measurements, we developed a new, distance-sensitive fluorescent reporter. Rather than relying on FRET, where stoichiometric and specific labeling of donor and acceptor is required to faithfully report on distance changes in bulk measurements, we employed a single-dye reporter system. In photo induced electron transfer (PET), fluorophores such as Atto655 can be quenched by a tryptophan in close proximity, through the formation of weakly fluorescent or non-fluorescent dye-tryptophan ground-state complexes⁴⁹ (Fig. 6c). Owing to the strong distance-dependence of PET, small-scale conformational changes result in “on-off” switching of fluorescence, yielding a change in fluorescence intensity but no shift in λ_{max} over a small distance range, typically about 5–10 Å⁴⁹.

To report only on the outward motion of TM6, we chose to label Leu 266 mutated to cysteine instead of the native Cys 265, as the former does not undergo inward to outward rotations upon activation, but points outwards in both active and inactive structures (Supplementary Fig. 9a). Based on the inactive and active $\beta_2\text{AR}$ crystal structures and dye simulations (Supplementary Fig. 9b), we speculated that a tryptophan residue introduced at the intracellular end of TM5 (L230W) would quench the fluorescence of Atto655 in the inactive, but considerably less in the active state, as the distance range and change between TM5 and TM6 that occurs upon activation should be compatible with PET-induced quenching. By simulating the conformational ensembles of Atto655 bound to Cys 266 in the inactive and active $\beta_2\text{AR}$ structures, we found an average dye-Trp 230 distance change of about ~ 5 Å upon receptor activation (Supplementary Fig. 9b), compatible with the reported quenching distance. We thus introduced mutations L230W and L266C into a minimal cysteine background $\beta_2\text{AR}$ ³³ and verified that the detergent-purified, Atto655-labeled $\beta_2\text{AR}$ 6 L230W:L266C construct retained wild-type ligand binding properties (Supplementary Fig. 10).

When measuring the steady-state fluorescence emission of Atto655-labeled $\beta_2\text{AR}$ 6 L230W:L266C, referred to as Atto- $\beta_2\text{AR}$ from here on, in the presence of saturating concentrations of epinephrine, we observe a $\sim 30\%$ increase in fluorescence intensity compared to unliganded receptor, compatible with an outward motion of TM6 and an

increased distance between Atto655 and the Trp 230 quencher on TM5 (**Fig. 6d**, Supplementary Fig. 11a). Given the short distance over which PET-quenching occurs, this observation likely reflects a TM6 displacement of $\sim 5\text{\AA}$ or more in approximately 30% of epinephrine-bound receptor. This is consistent with the fraction of receptor in an active conformation observed in double electron-electron resonance spectroscopy studies³¹. Interestingly, we observed a much smaller difference ($<10\%$) between unliganded and salmeterol-bound receptor (**Fig. 6d**, Supplementary Fig. 11a), suggesting that TM6 did not move sufficiently far away from TM5 in salmeterol-bound $\beta_2\text{AR}$ to reduce Atto655 quenching by Trp230. Based on the efficacy of salmeterol in G protein activation (60% of isoproterenol, Supplementary Fig. 7c) we would expect a much larger change in Atto- $\beta_2\text{AR}$ fluorescence in response to salmeterol if salmeterol and isoproterenol stabilized the same active state. Addition of Gs to salmeterol- and isoproterenol-bound Atto- $\beta_2\text{AR}$ led to a 1.8- and 2.2-fold increase in fluorescence intensity, respectively, compared to unliganded receptor (**Fig. 6d**, “+Gs” curves). This is consistent with the G protein stabilizing an active conformation in a larger fraction of receptor. Control measurements on a construct without the engineered L230W mutation showed little intensity change upon addition of agonists alone or together with Gs (Supplementary Fig 11b). In line with the difference in TM6 outward motion between the Nb80- and Nb71-bound structures, the Atto response in the presence of Nb80 is much larger than in the presence of Nb71, both for epinephrine and salmeterol (Supplementary Fig. 11c). This is similar to what we observed in the presence of Gs (**Fig. 6b,d**): when both ligand and Gs or nanobody are present, the TM6 receptor conformation is mainly stabilized by the intracellular binding protein and not the ligand. However, both of our fluorescence-based approaches in the absence of nanobody clearly suggest a difference in TM6 conformation between epinephrine- and salmeterol-bound receptors.

Discussion

$\beta_2\text{AR}$ s expressed in airway smooth muscle and epithelial cells mediate bronchodilation and fluid clearance, respectively, and are thus well-established targets for the treatment of asthma and COPD⁵⁰. The unusual pharmacological characteristics of salmeterol including the extremely high selectivity for $\beta_2\text{AR}$ and the long duration of action, which can be attributed to its long aryloxyalkyl tail, make it among the most commonly prescribed LABAs for treating asthma and COPD. Our structure revealed an additional site in the extracellular vestibule of $\beta_2\text{AR}$, the exosite, for the binding of the aryloxyalkyl tail, thus providing a structural basis for the prominent pharmacological action of salmeterol. It also resolves a long-standing debate as to the location of the exosite.

Our results also provide structural insights into the partial agonism and the biased signaling property of salmeterol, which are attributed to its saligenin ethanolamine group bound in the orthosteric binding pocket. Although the interactions with the receptor in the orthosteric binding pocket are very similar for the full agonist epinephrine and the partial agonist salmeterol, we observe subtle differences in hydrogen bonding interactions. Most notable is the absence of interactions between salmeterol and Asn 293^{6,55}, which is further supported by molecular dynamics simulations. The meta-hydroxyl of epinephrine forms a hydrogen bond with Asn 293^{6,55}, which is also hydrogen bonded with Ser 204^{5,43}. Our mutagenesis

studies suggest that this hydrogen bond network may be important for stabilizing TM6 in a conformation necessary for efficient G protein coupling as well as GRK phosphorylation and/or arrestin coupling. Therefore, the less extensive polar interactions between salmeterol and Asn 293^{6,55} may contribute to the weaker efficacy of salmeterol in activating Gs and the near absence of β -arrestin recruitment, possibly due to inefficient coupling as a result of reduced GRK phosphorylation¹⁹.

The structure of salmeterol-bound β_2 AR revealed a smaller outward movement of TM6 compared to the epinephrine-bound β_2 AR. While this conformation implies a ‘partially active’ conformation of the receptor, it is likely imposed by the nanobody Nb71 rather than by the partial agonist salmeterol. Previous studies have suggested relatively weak allosteric coupling between the orthosteric site and the cytoplasmic site³¹. Thus it is difficult to capture the ligand-specific conformation of β_2 AR by protein crystallography. We took spectroscopic approaches using two different reporter systems to interrogate the conformational changes of β_2 AR associated with salmeterol, and showed that indeed TM6 did not achieve the same extent of outward motion compared to the full agonist epinephrine. This correlates with previous single-molecule investigations of TM6 motion in the β_2 AR³³, and provides a structural basis for salmeterol’s weaker Gs efficacy and possibly ligand bias. Whether this mechanism applies to other GPCRs needs further investigation.

Online Methods

Receptor Constructs

All constructs have an N-terminal Flag tag. The *T4L- β_2 AR-ICL3*, consists of an N-terminal T4 lysozyme fusion to β_2 AR(29–365) ICL3, *i.e.* (235–263) with mutations M96T, M98T and N187E. The *β_2 AR-PN1* consists of β_2 (1–24) – TEV – β_2 (25–365) – 3C – β_2 (366–413), with “TEV” and “3C” indicating TEV protease and 3C protease cut sites, respectively. Additionally, mutations M96T, M98T, C378A, N187E and C406A were introduced, as previously described⁵¹. The *β_2 AR 6 L230W:L266C* consists of full-length WT receptor with a minimal cysteine background³³ (C77V, C265A, C327S, C341L, C378A, C406A), as well as mutations L230W and L266C and a C-terminal hexahistidine tag.

Expression, purification and labeling of β_2 AR constructs

Receptor constructs were expressed in *Sf9* insect cell cultures infected with recombinant baculovirus (BestBac, Expression Systems), and solubilized in *n*-dodecyl- β -D-maltoside (DDM) according to methods described previously⁵¹. The solubilized receptor was purified through M1 FLAG chromatography followed by alprenolol-sepharose chromatography to remove non-functional receptor⁵¹. A second M1 FLAG chromatography was applied such that the receptor-bound alprenolol could be removed for unliganded protein or exchanged for salmeterol.

For the *T4L- β_2 AR-ICL3*, after the protein was eluted from the M1 resin, the FLAG epitope tag of *T4L- β_2 AR-ICL3* was removed by the treatment of tobacco etch virus (TEV) protease (Invitrogen) for 3h at room temperature or overnight at 4°C. When necessary, a 50kDa MWCO Vivaspin concentrator (GE Healthcare) was used to concentrate the receptor.

The β_2 AR constructs used for fluorescence studies were concentrated and flash-frozen in the presence of 20% glycerol at a final concentration of 200 μ M. Aliquots were then stored at –80 °C until use.

Full-length PN1- β_2 AR was labeled with monobromobimane as previously described⁵². Briefly, FLAG pure receptor (~2 μ M) was incubated overnight on ice with 100 μ M TCEP and 20 μ M monobromobimane (Thermo Fisher Scientific). Subsequently, 5mM cysteine was added to quench the labeling reaction followed by alprenolol-sepharose chromatography as described above. A similar procedure was followed for labeling β_2 AR 6 L230W:L266C with Atto655-iodoacetamide (Atto-TEC).

G protein expression and purification

Wild-type Gs heterotrimer was expressed and purified as previously described³³. Following purification, the protein was dialyzed into 20mM HEPES pH 7.5, 100mM NaCl, 0.02%DDM, 100 μ M TCEP and 20 μ M GDP, concentrated, and flash-frozen in the presence of 20% glycerol at a final concentration of 200 μ M. Aliquots were then stored at –80 °C until use.

Preparation of Nb71 and Nb80

The recombinant Nb71 was generated in the same way as Nb80²⁵. These two nanobodies were screened from a same library of single-chain nanobody clones after immunizing a llama with purified agonist-bound β_2 AR reconstituted at high density into phospholipid vesicles. Nb71 was expressed in *E. coli* and purified by nickel affinity chromatography in a same manner as Nb80²⁵. The protein was then further purified by *cation exchange* using a Mono-S column (GE Healthcare), loading the protein at 20mM NaCl in 20mM MES pH 6.0 and eluting with a linear gradient from 50 to 500mM NaCl. In order to minimize severe precipitation of Nb71 over time, the purified protein was stored at a concentration below 5 mg/mL in 20mM Hepes, 1M NaCl.

Crystallization

Salmeterol bound receptor (~40mg/ml) was incubated with a 5.5-fold molar excess of Nb71 (~50mg/mL) for 1 hour on ice. Size exclusion chromatography was then performed to remove free Nb71. The purified complex was concentrated to ~60mg/mL for crystallization using the lipid cubic phase (LCP) method as previously described³⁵. The protein complex was reconstituted in monoolein containing 10% cholesterol at a 1:1.5 protein to lipid ratio (w/w). Reconstituted protein-lipid mixture drops of 30 nL were deposited in each well of a 96-well glass sandwich plate (Molecular Dimensions). The drop was then overlaid with 650nL of precipitant and the wells sealed with a glass coverslip. Diffraction-quality crystals were grown at 20°C in 31–34% PEG 400, 100mM HEPES pH 7.5, 1% 1,2,3-heptanetriol following 3 days of incubation at 20°C.

Data collection, structure determination and analysis

Crystals were harvested and frozen in liquid nitrogen directly without using additional cryo-protectant. Diffraction data from 24 different crystals were measured using the GM/CA-CAT microfocus beam at 23-ID-D (Advanced Photon Source, Argonne National Labs). The data

were processed with HKL2000 and the structure solved by molecular replacement using Phaser. Further model rebuilding was performed by using Coot and the structure was refined with Phenix. The validation of the final structural model was performed using MolProbity. The overall MolProbity score is 1.35. For the Ramachandran analysis, 96.8% atoms are in Ramachandran favored regions and 3.2% atoms are in Ramachandran allowed regions. Data processing and refinement statistics are shown in Supplementary Table 2.

The structure of the inactive β_2 AR (PDB ID 2RH1), the β_2 AR complexed with Nb80 (PDB ID 3P0G), the β_2 AR complexed with Gs (PDB ID 3SN6), the chain A of sabutamol bound β_1 AR (PDB ID 2Y04) were used for structural alignments in PYMOL based on C α only. The secondary structure of β_2 AR ICL2 was assigned by PYMOL and DSSP.

Reconstitution of β_2 AR in HDL particles for Octet Red measurements

The β_2 AR was reconstituted in high-density lipoprotein (HDL) particles using established methods⁵¹. The scaffold protein ApoA-I used for reconstitution was purified as previously described⁵¹. Purified ApoA-I was biotinylated for 30 min at room temperature using NHS-PEG4-biotin (Thermo) at a 1:1 molar ratio in a buffer composed of 20 mM HEPES, pH 8.0, 100mM NaCl, 1mM EDTA, 5 mM sodium cholate. Following the labeling reaction, unreacted biotin was quenched by the addition of Tris-HCl, pH 8.0 to a final concentration of 20 mM. Biotinylated protein was separated from free biotin by size exclusion chromatography on Superdex 75 HR 10/30. FLAG-tagged β_2 AR was incorporated into HDL particles using biotinylated ApoA-I and receptor-containing HDL particles were isolated using M1 anti-FLAG immunoaffinity chromatography.

Nanobody binding to β_2 AR in biotinylated HDL particles was monitored using the OctetRED biolayer interferometry system (Pall FortéBio) using streptavidin-coated biosensors (Pall FortéBio). Sensors were hydrated for at least 10 min at room temperature in assay buffer (20 mM Tris-HCl pH 7.4, 136 mM NaCl, 2.7 mM KCl, 1 mM EDTA, 0.02% w/v ascorbic acid, 0.05% w/v BSA), then incubated with biotinylated β_2 AR-HDL (~100 nM) for 10 min at room temperature prior to loading the sensors onto the OctetRED instrument. All steps on the OctetRED were performed at 25 °C with the assay plate shaking at 1,000 rpm. After an initial baseline reading, sensors were dipped into wells containing assay buffer with a saturating concentration of agonist (100 μ M Epinephrine, 0.1 μ M BI-167107, or 1 μ M Salmeterol) and incubated for 20 min to equilibrate β_2 AR with agonist. The sensors were transferred to wells containing assay buffer plus agonist and nanobody (1, 3.2, 10, 32, 100, or 320 nM) for 5 min to monitor nanobody association. Nanobody dissociation was monitored by then transferring the sensors to wells containing assay buffer plus agonist for 30 min. Nonspecific nanobody binding at each concentration was measured in a parallel experiment in which sensors were loaded with empty HDL. Buffer-only controls were also included in each experiment to correct for baseline drift. Data were first analyzed using Octet Data Analysis 7.0 software (Pall FortéBio) to remove baseline and nonspecific binding, and the processed data were exported to Prism 6 (GraphPad) for curve fitting. All association and dissociation curves were fit using single-phase exponential association or decay.

BRET measurements for Gs activation, β -arrestin recruitment and β_2 AR conformational change in live cells.

HEK293T cells used for the BRET assays were grown in Dulbecco's modified Eagle's medium (DMEM), supplemented with 10% newborn calf serum (NCS), at 37 °C with 5% CO₂. Cells were detached with trypsin-EDTA and transfected with 2.5 μ g of total DNA per 10⁶ cells, using linear polyethylenimine (PEI, Polysciences) as transfecting agent, at a ratio of 3:1 (PEI:DNA). Gs activation was evaluated with Gs-117-RLucII/G β 1/G γ 1-GFP10⁴¹ and β -arrestin recruitment with CAAX-rGFP/ β -arr2-RLucII⁴² sensors, in presence of WT 3HA- β_2 AR or mutant receptors. The conformational changes were detected with the NY- β_2 AR sensor⁵³. Directly after transfection, cells were plated in 96-well white plates (Greiner) at a density of 50,000 cells/well, and incubated for 48 h. After that period, the plates were washed with PBS and assay buffer (Hank's balanced salt solution (HBSS)) was added. Cells were stimulated with the ligands during 5 or 15 min for evaluating, respectively, Gs activation or β -arrestin recruitment and conformational changes. Coelenterazine 400a (2.5 μ M) was added 5 min before the reads. BRET was monitored using a TriStar LB942 microplate reader (Berthold) equipped with a 410/80 nm donor filter and a 515/40 nm acceptor filter (for Gs activation and β -arrestin recruitment) or a 485/20 nm donor filter and a 530/25 nm acceptor filter (for receptor conformational changes). BRET ratio was calculated by dividing the acceptor emission by the donor emission. The data were analyzed with Prism (Graphpad) using "dose-response- stimulation log(agonist) vs normalized response- variable slope" with the constraint of sharing the hill slope across all data sets.

Molecular Dynamics Simulations

We simulated the β_2 -adrenergic receptor bound to the partial agonist salmeterol as well as the full agonist epinephrine. We initiated these simulations from crystal structures of the receptor bound to each of these ligands. Each of the crystal structures we used includes a nanobody that binds to the intracellular side of the receptor and stabilizes an active or intermediate receptor state: Nb71 for salmeterol and Nb6B9 for epinephrine²⁹.

We performed three simulations of β_2 AR–salmeterol–Nb71 and three simulations of β_2 AR–epinephrine–Nb6B9. Each of the crystallized constructs was a β_2 AR–T4 lysozyme (T4L) fusion protein, with T4L replacing the receptor's N-terminus. T4L was omitted from all simulations, while all other resolved residues were included. The majority of ICL3 was absent in all simulations, because it was deleted from the crystallized construct in β_2 AR–salmeterol–Nb71 and β_2 AR–epinephrine–Nb6B9. Because the simulations were performed before the published coordinates had been finalized, they were initiated using coordinates that differed very slightly from the published ones (root mean squared deviation below 0.3 Å, computed over all resolved receptor Ca atoms); these differences were much smaller than the typical motions of the atoms in simulation. In all simulations, a palmitoyl group not resolved but presumed to be present in the crystallized constructs was added to Cys341 using Maestro (Schrödinger LLC, New York, NY).

The β_2 AR was embedded in a hydrated lipid bilayer in all simulations; all atoms (including those in lipids and water) were represented explicitly. Hydrogen atoms were added to the crystal structures using Maestro, as described previously, and receptor chain termini were

capped with neutral groups (acetyl and methylamide). Titratable residues other than Glu122^{3,41} were left in their dominant protonation state at pH 7.0. Glu122^{3,41}, which faces the lipid bilayer, was neutral (protonated) in all simulations.

Prepared protein structures were inserted into an equilibrated bilayer solvated with 0.15 M NaCl, using a previously described protocol⁵⁴. The bilayer consisted of palmitoyl-oleoyl-phosphatidylcholine, with 24% palmitoyl-oleoyl-phosphatidylserine in the inner membrane leaflet. Simulated systems initially measured roughly $71 \times 71 \times 115 \text{ \AA}^3$ and contained approximately 140 lipid molecules, 12,000 water molecules, 32 chloride ions, and 40 sodium ions.

We also performed three simulations of $\beta_2\text{AR}$ -salmeterol with the nanobodies removed (but otherwise starting from the same structures as above). Simulation setup was as described above, except that the removal of the nanobody allowed the simulated volume to be somewhat smaller. These simulations initially measured roughly $69 \times 69 \times 85 \text{ \AA}^3$ and contained approximately 120 lipid molecules, 7200 water molecules, 19 chloride ions, and 30 sodium ions.

We used the CHARMM-h force field for proteins. We used the CHARMM36 lipid force field, along with standard CHARMM salt ion parameters and the CHARMM TIP3P model for water. Parameters for palmitoyl-cysteine were as described previously^{27,54}, and parameters for epinephrine were obtained by adapting previously published parameters for isoproterenol⁵⁵. Parameters for salmeterol were obtained from the ParamChem server. Full parameter sets are available upon request.

Each simulation consisted of a 50-ns equilibration run followed by a longer production run. Systems were equilibrated in the NPT ensemble (310 K, 1 bar, Martyna-Tuckerman-Klein Nosé-Hoover chain coupling scheme using a multigrator, with initial velocities sampled from the Boltzmann distribution and with $5 \text{ kcal mol}^{-1} \text{ \AA}^{-2}$ harmonic position restraints applied to the protein and ligand atoms, which were tapered off linearly over 50 ns. Production simulations used the same integrator, pressure and temperature, and were initiated from the final snapshot of the corresponding equilibration simulation. All simulations were performed on an Anton 1 computer⁵⁶.

All bond lengths to hydrogen atoms were constrained using M-SHAKE. An r-RESPA integrator was used with a time step of 2.5 fs, and long-range electrostatics were computed every 7.5 fs. Long-range electrostatics were computed in reciprocal space with the *u*-series method⁵⁷.

Simulation snapshots were saved every 180 ps. For the purposes of evaluating the fraction of time a hydrogen bond was formed in simulation, such a bond was considered to be formed in snapshots in which the relevant non-hydrogen atoms were within 3.0 \AA of one another. Because the bound ligands shifted pose during the later parts of certain simulations (possibly as a result of motion of the nanobodies, which are not held in place by crystallographic contacts), we used the first microsecond of each simulation for these analyses. Each error bar was calculated as standard error of the mean across three simulations.

Dye modeling

The structure of the iodoacetamide derivative of the Atto655 dye (Atto-TEC GmbH) was obtained from PubChem (CID 16218785) and optimized using Avogadro and the GAFF force field. The structures of β_2 AR in the active (PDB ID 3SN6) and inactive conformations (PDB ID 2RH1) were retrieved from the RCSB PDB and mutated (L230W and L266C) using PyMOL. Parameters for the dye molecule attached to a cysteine residue were obtained using PRODRG and manually edited to enforce planarity of the ring system of the dye. The Crystallography and NMR System (CNS) software, version 1.3⁵⁸, was used to attach the dye to L266C and simulate its positions using rigid-body docking and multi-trial simulated annealing, respectively, as done previously by Brunger and co-workers⁵⁹. The entire receptor structure was kept rigid, except for the side-chain atoms of L230W and L266C. Distances between the centers of mass of the tryptophan side-chain atoms and center of mass of the ring system of the dye were calculated for each generated model (300 for each conformation of β_2 AR).

Fluorescence measurements on purified receptor in detergent solution

Bimane-labeled and Atto-labeled receptors were used at respective concentrations of 0.2 μ M and 0.1 μ M in buffer containing 20mM Hepes pH 7.4, 100mM NaCl, 0.02% (w/v) DDM and 0.002% (w/v) cholesterol hemisuccinate. Salmeterol and epinephrine stocks were prepared as 50mM and 100mM solutions in DMSO and added at indicated final concentrations. Ligand concentrations were chosen to achieve saturation of detergent-solubilized receptor. To avoid any non-specific vehicle effects, care was taken to obtain the same final concentration of DMSO in all samples. Where indicated, Gs was added to a final concentration of 2 μ M. To allow efficient ligand binding and full equilibration, samples were incubated at the final concentrations used for 1 hour in the dark prior to measurements. Fluorescence data was collected in a quartz cuvette with 500 μ L of sample using FluorEssence v3.8 software on a Fluorolog instrument (Horiba) in photon counting mode. Bimane fluorescence was measured by excitation at 370nm with excitation and emission bandwidth passes of 4nm, and emission spectra were recorded from 410 to 510 nm in 1nm increments and 1s integration time. Atto fluorescence was measured by excitation at 650nm with excitation and emission bandwidth passes of 5nm, and emission spectra were recorded from 660 to 730 nm in 1nm increments and 1s integration time. Measurements were performed in triplicate.

Radioligand binding assays

Binding curves were obtained by incubating the DDM purified wild-type, bimane- and Atto655-labeled receptors in the presence of M1 FLAG-sepharose and 2 mM Ca^{2+} , under shaking at room temperature for 1.5h. The antagonist [^3H]-dihydroalprenolol (DHA) (PerkinElmer) was used to obtain saturation binding curves. Competition binding measurements for salmeterol and epinephrine were performed in a similar way, using DHA at a concentration slightly above K_d , as determined by saturation binding. Non-specific binding was accounted for by measuring in the presence of 10 μ M cold alprenolol. Beads were harvested using a 48-well Brandell harvester and counted in a LS6000TA scintillator (Beckman) using Cytoscint (MP Biomedical).

Statistical Analysis.

Statistical significance of hydrogen bond duration from MD trajectories (Fig. 5a) was assessed using the one-sided Welch's unequal variances t-test. Statistical significance of the binding affinities (Supplementary Table 1) was assessed using Ordinary One-way ANOVA (Tukey) test at a multiplicity adjusted P value = 0.05. Statistical significance of the fitted mean logK_i values (Supplementary Fig. 1) was assessed using a one-way ANOVA Tukey test at a P values of 0.05 (adjusted for multiple comparisons).

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was supported by National Institutes of Health grants R01NS028471 (B.K.K.), the Canadian Institute for Health Research foundation grant FDN-148431 (M.B.), the American Heart Association Postdoctoral fellowship (17POST33410958) (M.M.) and Predoctoral Fellowship (13PRE17110027) (J.P.M.), a studentship from the FRQ-S (L.P.P.) and the NIH Pharmacological Sciences Training Program (T32GM007767) (J.P.M.). B.K.K. is supported by the Chan Zuckerberg Biohub. M.B. Holds a Canada Research Chair in Signal Transduction and Molecular Pharmacology. The authors thank J. Gullingsrud for assistance with MD software.

References

1. Kenakin T Drug efficacy at G protein-coupled receptors. *Annu Rev Pharmacol Toxicol* 42, 349–79 (2002). [PubMed: 11807176]
2. Zhu BT Rational design of receptor partial agonists and possible mechanisms of receptor partial activation: a theory. *J Theor Biol* 181, 273–91 (1996). [PubMed: 8869127]
3. Cazzola M & Donner CF Long-acting beta2 agonists in the management of stable chronic obstructive pulmonary disease. *Drugs* 60, 307–20 (2000). [PubMed: 10983735]
4. Baker JG, Proudman RG & Hill SJ Salmeterol's extreme beta2 selectivity is due to residues in both extracellular loops and transmembrane domains. *Mol Pharmacol* 87, 103–20 (2015). [PubMed: 25324048]
5. Ferguson GT, Funck-Brentano C, Fischer T, Darken P & Reisner C Cardiovascular safety of salmeterol in COPD. *Chest* 123, 1817–24 (2003). [PubMed: 12796155]
6. Twentyman OP, Finnerty JP, Harris A, Palmer J & Holgate ST Protection against allergen-induced asthma by salmeterol. *Lancet* 336, 1338–42 (1990). [PubMed: 1978163]
7. Ball DI et al. Salmeterol, a novel, long-acting beta 2-adrenoceptor agonist: characterization of pharmacological activity in vitro and in vivo. *Br J Pharmacol* 104, 665–71 (1991). [PubMed: 1686740]
8. Johnson M et al. The pharmacology of salmeterol. *Life Sci* 52, 2131–43 (1993). [PubMed: 8099695]
9. Calverley PM et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. *N Engl J Med* 356, 775–89 (2007). [PubMed: 17314337]
10. Wijesinghe M, Perrin K, Harwood M, Weatherall M & Beasley R The risk of asthma mortality with inhaled long acting beta-agonists. *Postgrad Med J* 84, 467–72 (2008). [PubMed: 18940948]
11. Weatherall M, Wijesinghe M, Perrin K, Harwood M & Beasley R Meta-analysis of the risk of mortality with salmeterol and the effect of concomitant inhaled corticosteroid therapy. *Thorax* 65, 39–43 (2010). [PubMed: 20029037]
12. Coleman RA, Johnson M, Nials AT & Vardey CJ Exosites: their current status, and their relevance to the duration of action of long-acting beta 2-adrenoceptor agonists. *Trends Pharmacol Sci* 17, 324–30 (1996). [PubMed: 8885698]

13. Clark RB, Allal C, Friedman J, Johnson M & Barber R Stable activation and desensitization of beta 2-adrenergic receptor stimulation of adenylyl cyclase by salmeterol: evidence for quasi-irreversible binding to an exosite. *Mol Pharmacol* 49, 182–9 (1996). [PubMed: 8569705]
14. Green SA, Spasoff AP, Coleman RA, Johnson M & Liggett SB Sustained activation of a G protein-coupled receptor via “anchored” agonist binding. Molecular localization of the salmeterol exosite within the 2-adrenergic receptor. *J Biol Chem* 271, 24029–35 (1996). [PubMed: 8798639]
15. Isogaya M et al. Identification of a key amino acid of the beta2-adrenergic receptor for high affinity binding of salmeterol. *Mol Pharmacol* 54, 616–22 (1998). [PubMed: 9765503]
16. Rong Y et al. Probing the salmeterol binding site on the beta 2-adrenergic receptor using a novel photoaffinity ligand, [(125)I]iodoazidosalmeterol. *Biochemistry* 38, 11278–86 (1999). [PubMed: 10471277]
17. Gimenez LE, Baameur F, Vayttaden SJ & Clark RB Salmeterol Efficacy and Bias in the Activation and Kinase-Mediated Desensitization of beta2-Adrenergic Receptors. *Mol Pharmacol* 87, 954–64 (2015). [PubMed: 25784721]
18. van der Westhuizen ET, Breton B, Christopoulos A & Bouvier M Quantification of ligand bias for clinically relevant beta2-adrenergic receptor ligands: implications for drug taxonomy. *Mol Pharmacol* 85, 492–509 (2014). [PubMed: 24366668]
19. Tran TM et al. Characterization of agonist stimulation of cAMP-dependent protein kinase and G protein-coupled receptor kinase phosphorylation of the beta2-adrenergic receptor using phosphoserine-specific antibodies. *Mol Pharmacol* 65, 196–206 (2004). [PubMed: 14722251]
20. Drake MT et al. beta-arrestin-biased agonism at the beta2-adrenergic receptor. *J Biol Chem* 283, 5669–76 (2008). [PubMed: 18086673]
21. Carter AA & Hill SJ Characterization of isoprenaline- and salmeterol-stimulated interactions between beta2-adrenoceptors and beta-arrestin 2 using beta-galactosidase complementation in C2C12 cells. *J Pharmacol Exp Ther* 315, 839–48 (2005). [PubMed: 16051698]
22. Moore RH et al. Salmeterol stimulation dissociates beta2-adrenergic receptor phosphorylation and internalization. *Am J Respir Cell Mol Biol* 36, 254–61 (2007). [PubMed: 16980556]
23. Walker JK & DeFea KA Role for beta-arrestin in mediating paradoxical beta2AR and PAR2 signaling in asthma. *Curr Opin Pharmacol* 16, 142–7 (2014). [PubMed: 24907413]
24. Billington CK, Penn RB & Hall IP beta2 Agonists. *Handb Exp Pharmacol* 237, 23–40 (2017). [PubMed: 27878470]
25. Rasmussen SG et al. Structure of a nanobody-stabilized active state of the beta(2) adrenoceptor. *Nature* 469, 175–80 (2011). [PubMed: 21228869]
26. Rasmussen SG et al. Crystal structure of the beta2 adrenergic receptor-Gs protein complex. *Nature* 477, 549–55 (2011). [PubMed: 21772288]
27. Rosenbaum DM et al. Structure and function of an irreversible agonist-beta(2) adrenoceptor complex. *Nature* 469, 236–40 (2011). [PubMed: 21228876]
28. Warne T et al. The structural basis for agonist and partial agonist action on a beta(1)-adrenergic receptor. *Nature* 469, 241–4 (2011). [PubMed: 21228877]
29. Ring AM et al. Adrenaline-activated structure of beta2-adrenoceptor stabilized by an engineered nanobody. *Nature* 502, 575–579 (2013). [PubMed: 24056936]
30. Nygaard R et al. The dynamic process of beta(2)-adrenergic receptor activation. *Cell* 152, 532–42 (2013). [PubMed: 23374348]
31. Manglik A et al. Structural Insights into the Dynamic Process of β 2-Adrenergic Receptor Signaling. *Cell* 161, 1101–1111 (2015). [PubMed: 25981665]
32. Sounier R et al. Propagation of conformational changes during mu-opioid receptor activation. *Nature* 524, 375–8 (2015). [PubMed: 26245377]
33. Gregorio GG et al. Single-molecule analysis of ligand efficacy in β 2AR-G-protein activation. *Nature* 547, 68–73 (2017). [PubMed: 28607487]
34. Staus DP et al. Regulation of beta2-adrenergic receptor function by conformationally selective single-domain intrabodies. *Mol Pharmacol* 85, 472–81 (2014). [PubMed: 24319111]
35. Caffrey M Crystallizing membrane proteins for structure determination: use of lipidic mesophases. *Annual review of biophysics* 38, 29–51 (2009).

36. Baker JG The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors. *Br J Pharmacol* 160, 1048–61 (2010). [PubMed: 20590599]
37. Kruse AC et al. Activation and allosteric modulation of a muscarinic acetylcholine receptor. *Nature* 504, 101–6 (2013). [PubMed: 24256733]
38. Fronik P, Gaiser BI & Sejer Pedersen D Bitopic Ligands and Metastable Binding Sites: Opportunities for G Protein-Coupled Receptor (GPCR) Medicinal Chemistry. *J Med Chem* 60, 4126–4134 (2017). [PubMed: 28140580]
39. Wieland K, Zuurmond HM, Krasel C, Ijzerman AP & Lohse MJ Involvement of Asn-293 in stereospecific agonist recognition and in activation of the beta 2-adrenergic receptor. *Proc Natl Acad Sci U S A* 93, 9276–81 (1996). [PubMed: 8799191]
40. Liapakis G, Chan WC, Papadokostaki M & Javitch JA Synergistic contributions of the functional groups of epinephrine to its affinity and efficacy at the beta2 adrenergic receptor. *Mol Pharmacol* 65, 1181–90 (2004). [PubMed: 15102946]
41. Thomsen ARB et al. GPCR-G Protein-β-Arrestin Super-Complex Mediates Sustained G Protein Signaling. *Cell* 166, 907–919 (2016). [PubMed: 27499021]
42. Namkung Y et al. Monitoring G protein-coupled receptor and beta-arrestin trafficking in live cells using enhanced bystander BRET. *Nat Commun* 7, 12178 (2016). [PubMed: 27397672]
43. Gregorio GG et al. Single-molecule analysis of ligand efficacy in beta2AR-G-protein activation. *Nature* 547, 68–73 (2017). [PubMed: 28607487]
44. Picard L-P, Schönege AM, Lohse MJ & Bouvier M Bioluminescence resonance energy transfer-based biosensors allow monitoring of ligand- and transducer-mediated GPCR conformational changes. *Communications Biology* 1(2018).
45. Yao XJ et al. The effect of ligand efficacy on the formation and stability of a GPCR-G protein complex. *Proc Natl Acad Sci U S A* 106, 9501–6 (2009). [PubMed: 19470481]
46. Dawaliby R et al. Allosteric regulation of G protein-coupled receptor activity by phospholipids. *Nat Chem Biol* 12, 35–9 (2016). [PubMed: 26571351]
47. Schafer CT, Fay JF, Janz JM & Farrens DL Decay of an active GPCR: Conformational dynamics govern agonist rebinding and persistence of an active, yet empty, receptor state. *Proc Natl Acad Sci U S A* 113, 11961–11966 (2016). [PubMed: 27702898]
48. Fay JF & Farrens DL Purification of Functional CB1 and Analysis by Site-Directed Fluorescence Labeling Methods. *Methods Enzymol* 593, 343–370 (2017). [PubMed: 28750810]
49. Doose S, Neuweiler H & Sauer M A close look at fluorescence quenching of organic dyes by tryptophan. *Chemphyschem* 6, 2277–85 (2005). [PubMed: 16224752]
50. Cazzola M, Calzetta L & Matera MG beta(2) -adrenoceptor agonists: current and future direction. *Br J Pharmacol* 163, 4–17 (2011). [PubMed: 21232045]
51. Dawaliby R et al. Allosteric regulation of G protein-coupled receptor activity by phospholipids. *Nature Chemical Biology* 12, 35–41 (2015). [PubMed: 26571351]
52. Rosenbaum DM et al. GPCR engineering yields high-resolution structural insights into beta2-adrenergic receptor function. *Science (New York, N.Y.)* 318, 1266–73 (2007).
53. Picard LP, Schonegge AM, Lohse MJ & Bouvier M BRET-based biosensors to monitor ligand- and transducer-mediated GPCR conformational changes. (*Communications Biology*, 2018).
54. Dror RO et al. Identification of two distinct inactive conformations of the beta2-adrenergic receptor reconciles structural and biochemical observations. *Proc Natl Acad Sci U S A* 106, 4689–94 (2009). [PubMed: 19258456]
55. Dror RO et al. Pathway and mechanism of drug binding to G-protein-coupled receptors. *Proceedings of the National Academy of Sciences of the United States of America* 108, 13118–23 (2011). [PubMed: 21778406]
56. Shaw DE. Millisecond-scale molecular dynamics simulations on Anton; *Proceedings of the Conference on High Performance Computing Networking, Storage and Analysis*; Portland, Oregon. ACM; 2009. 1–11.
57. Shaw DE. Anton 2: Raising the bar for performance and programmability in a special-purpose molecular dynamics supercomputer; *Sc14: International Conference for High Performance Computing, Networking, Storage and Analysis*; 2014. 41–53.

58. Brunger AT Version 1.2 of the Crystallography and NMR system. *Nature Protocols* 2, 2728 (2007). [PubMed: 18007608]
59. Choi UB et al. Single-molecule FRET-derived model of the synaptotagmin 1-SNARE fusion complex. *Nat Struct Mol Biol* 17, 318–24 (2010). [PubMed: 20173763]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 1: Crystal structure of salmeterol-bound β_2 AR.

a. Chemical structures of β_2 AR ligands: partial agonists salmeterol and salbutamol; full agonists epinephrine and BI-167107. The respective pharmacophores that bind the orthosteric ligand binding pocket are highlighted in purple, and the aryloxyalkyl tail of salmeterol, which binds the exosite, is highlighted in blue. **b.** Overall ribbon representation of the salmeterol-bound β_2 AR – Nb71 complex structure. The T4L lysozyme fusion facilitates crystallization, while Nb71 stabilizes the active, salmeterol-bound (orange spheres) β_2 AR. **c.** Cross-section through the receptor, with the interior in black, highlighting salmeterol (orange spheres) occupying the orthosteric site and the exosite.




Figure 2: Structural features of the β_2 AR-salmeterol-Nb71 complex.

a,b,c. Overlay of inactive carazolol bound receptor (grey), Nb71 and salmeterol bound β_2 AR (purple) and the BI-167107 bound β_2 AR - Gs complex (green and pink, respectively).

a. Side view (inset) and cytoplasmic view of TM6, showing the position of TM6 relative to the helical bundle. The extent of TM6 movement, indicated by black arrows, was measured using the Ca of Glu268 as reference point. **b.** Rearrangement of Pro211^{5,50}, Ile121^{3,40} and Phe282^{6,44} and the associated outward movement of the cytoplasmic end of TM6. The inactive structure of β_2 AR is colored silver. The active structures of β_2 AR are colored blue (coupled with salmeterol and Nb71), cyan (coupled with epinephrine and 6B9) and green (coupled with BI-167107 and Gs). **c.** Extracellular (top) view of β_2 AR, with major conformational changes between structures indicated by red arrows and ligands in stick representation.




Figure 3: Salmeterol exosite and receptor subtype-selectivity determinants.

a. Side and **b.** top view of β_2 AR, with stick representation of salmeterol (orange). **c.** Spherical representation of the salmeterol aryloxyalkyl moiety (orange) and the β_2 AR (blue). **d.** Residues important for interaction and specificity are highlighted in yellow and labeled. With the exception of Y308 (indicated by a red arrow), the amino acids that form the orthosteric binding pocket for epinephrine are identical between β_1 AR and β_2 AR. **e.** Comparison of the ligand binding sites between β_2 AR (left panel) bound to salmeterol (orange sticks) and M2R (right panel) bound to the allosteric modulator LY2119620 (green sticks).




Figure 4: Hydrogen bond interactions in the orthosteric site and re-arrangement of the ligand binding pocket.

Comparison of ligand-mediated hydrogen bonds (black dashed lines) in **a.** epinephrine-bound and **b.** salmeterol-bound β_2 AR.




Figure 5: Ligands and specific residues in the orthosteric site modulate hydrogen bonding and signaling outcome.

a. Frequency of hydrogen bonding between Ser203^{5.42} / Asn293^{6.55} and the ligand *m*-OH group, Ser207^{5.46} and the ligand *p*-OH group, and Asn312^{7.39} and the ligand β -OH group in MD simulations of receptor bound to epinephrine or salmeterol. Individual datapoints (black dots) and SEM (error bars) of 3 independent experiments are shown. Statistical significance was assessed using the one-side Welch's unequal variances t-test (p values: Ser203^{5.42}=0.00003; Ser207^{5.46}=0.08; Asn293^{6.55}=0.004; Asn312^{7.39}=0.01). The actual statistical significance of the differences (e.g. for Ser207) may be better than computed, as each of the data points is based on a trajectory with thousands of samples. **b,c.** BRET-based assays monitoring β -arrestin2 recruitment and G-protein activation on wild-type and mutant β_2 AR constructs. Data represent the mean (symbols) \pm SEM (error bars) of 3 independent experiments. Error bars shorter than the height of the symbol are not shown.




Figure 6: Spectroscopic interrogation of ligand-induced changes in TM6 conformation on detergent-solubilized, purified labeled receptor.

a,c. Schematic representation of labeled receptor constructs used to probe the outward motion of TM6. The β_2 AR transmembrane helices 1–5 and 7 are shown as grey cylinders. The blue cylinders represent TM6 in the inactive (light blue) and active (dark blue) conformation, with the labels attached at the intracellular end of TM6 depicted according to their overall structure. The bimane fluorophore (teal) is an environment-sensitive reporter, while the Atto655 dye (pink) is quenched in a distance-dependent way by an engineered tryptophan (L230W, in yellow). **b,d.** Steady-state fluorescence emission spectra of bimane-labeled and Atto655-labeled receptor in the presence of epinephrine or salmeterol. The spectra are normalized relative to unliganded receptor (apo, light blue curve) and show the fluorescence dose-response of receptor up to saturating ligand concentrations, in the absence and presence of G protein. Data is plotted as mean (curves) and standard deviation (error bars) of triplicate measurements.